Additionally, RIP1 and RIP3 expressions in cancer cells are inclined to be decreased because of genetic mutations or hypoxic induction; thus, pharmaceutical companies may develop new agents that directly target and activate MLKL. The gene discussed is RIPK3; the disease is cancer.